Towards personalized antithrombotic management with drugs and devices across the cardiovascular spectrum
- 8 October 2021
- journal article
- review article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 43 (10) , 940-958
Abstract
Intravascular thrombus formation and embolization are among the most frequent events leading to a number of cardiovascular conditions with high morbidity and mortality. The underlying causes are stasis of the circulating blood, genetic and acquired coagulation disorders, and reduced antithrombotic or prothrombotic properties of the vascular wall (Virchow’s triad). In the venous system, intravascular thrombi can cause venous thrombosis and pulmonary and even peripheral embolism including ischaemic stroke [through a patent foramen ovale (PFO)]. Thrombi in the left atrium and its appendage or ventricle form in the context of atrial fibrillation and infarction, respectively. Furthermore, thrombi can form on native or prosthetic aortic valves, within the aorta (in particular at sites of ulcers, aortic dissection, and abdominal aneurysms), and in cerebral and peripheral arteries causing stroke and critical limb ischaemia, respectively. Finally, thrombotic occlusion may occur in arteries supplying vital organs such the heart, brain, kidney, and extremities. Thrombus formation and embolization can be managed with anticoagulants and devices depending on where they form and embolize and on patient characteristics. Vitamin K antagonists are preferred in patients with mechanical valves, while novel oral anticoagulants are first choice in most other cardiovascular conditions, in particular venous thromboembolism and atrial fibrillation. As anticoagulants are associated with a risk of bleeding, devices such as occluders of a PFO or the left atrial appendage are preferred in patients with an increased bleeding risk. Platelet inhibitors such as aspirin and/or P2Y12 antagonists are preferred in the secondary prevention of coronary artery disease, stroke, and peripheral artery disease either alone or in combination depending on the clinical condition. A differential and personalized use of anticoagulants, platelet inhibitors, and devices is recommended and reviewed in this article.Keywords
This publication has 231 references indexed in Scilit:
- Oral Apixaban for the Treatment of Acute Venous ThromboembolismNew England Journal of Medicine, 2013
- Stroke and Bleeding in Atrial Fibrillation with Chronic Kidney DiseaseNew England Journal of Medicine, 2012
- Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary EmbolismNew England Journal of Medicine, 2012
- Antithrombotic Therapy in Peripheral Artery DiseaseChest, 2012
- Stenting versus Aggressive Medical Therapy for Intracranial Arterial StenosisNew England Journal of Medicine, 2011
- Atherosclerotic Disease of the Proximal Aorta and the Risk of Vascular Events in a Population-Based CohortStroke, 2009
- Aortic Arch Plaques and Risk of Recurrent Stroke and DeathCirculation, 2009
- Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent StrokeNew England Journal of Medicine, 2008
- Aortic Atherosclerosis, Hypercoagulability, and StrokeJACC, 2008
- Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.Stroke, 1993